What Researchers Did
Researchers developed clinical guidelines for the diagnosis and management of osteonecrosis of the jaw (ONJ).
What They Found
Researchers found that over 90% of osteonecrosis of the jaw (ONJ) cases occur in oncology patients receiving high-dose antiresorptive therapy, with an incidence of 1-90 per 100,000 patient-years in osteoporosis patients. Prevalence in oncology patients can be as high as 18.6%, with additional risk factors including oral surgical procedures and periodontal disease.
What This Means for Canadian Patients
Canadian patients receiving bisphosphonates or denosumab, particularly for cancer, should prioritize excellent oral hygiene and regular dental check-ups to minimize the risk of ONJ. If ONJ develops, patients can expect a range of management options, from conservative treatments like antimicrobial rinses and antibiotics to surgical intervention for advanced cases.
Canadian Relevance
This clinical guideline, developed by Canadian researchers, provides essential recommendations for the diagnosis and management of ONJ, directly impacting Canadian clinical practice and patient care.
Study Limitations
The guideline acknowledges limitations in current data regarding the causal relationship between antiangiogenic agents and ONJ, indicating a need for further evidence.